3-?-tropanyl 2-(4-Cl-phenoxy)butyrate (SM 21): A Review of the Pharmacological Profile of a Novel Enhancer of Cholinergic Transmission
- 1 December 1997
- journal article
- review article
- Published by Wiley in CNS Drug Reviews
- Vol. 3 (4) , 346-362
- https://doi.org/10.1111/j.1527-3458.1997.tb00332.x
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Central cholinergic antinociception induced by 5HT4 agonists: BIMU 1 and BIMU 8Life Sciences, 1996
- Synthesis and enantioselectivity of the enantiomers of PG9 and SM21, new potent analgesic and cognition-enhancing drugsChirality, 1996
- R-(+)-hyoscyamine: The first selective antagonist for guinea-pig uterus muscarinic receptor subtypeLife Sciences, 1993
- Cross-tolerance between baclofen and bicuculline antinociceptionPharmacological Research, 1990
- κ‐Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the ratBritish Journal of Pharmacology, 1988
- Cholinergic agonist and antagonist interactions on motor nerve endings of the rat—evidence for the involvement of presynaptic receptors in the regulation of acetylcholine releaseGeneral Pharmacology: The Vascular System, 1987
- Pharmacologic evidence for direct dopaminergic regulation of striatal acetylcholine releaseLife Sciences, 1986
- Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonistLife Sciences, 1986
- Further evidence for the involvement of D2, but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmissionLife Sciences, 1982
- The central action of a metabolite of tremorineLife Sciences, 1962